Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has provided an announcement.
Sihuan Pharmaceutical Holdings Group has achieved a significant milestone with its subsidiary, Meiyan Space, obtaining Class III medical device registration approval from China’s National Medical Products Administration for its Poly-L-lactic Acid Facial Filler (PLLA filler). This development strengthens Sihuan’s position in the regenerative medical aesthetic market, highlighting its technological leadership and competitive advantage. The approval is expected to drive the company’s growth in the medical aesthetic segment, supported by the rapidly expanding market for regenerative biomaterials in China.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company operating in the pharmaceutical industry, with a focus on developing and commercializing medical aesthetic products. Its subsidiary, Meiyan Space, is dedicated to building a comprehensive medical aesthetics product matrix in China, leveraging pharmaceutical rigor and innovation.
YTD Price Performance: 146.94%
Average Trading Volume: 200
Technical Sentiment Signal: Sell
Current Market Cap: $793.6M
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.